In a pre-clinically study, researchers in Argentina have demonstrated the safety and pharmacokinetic performance of a new nasal spray formulation designed to suppress the replication of SARS-CoV-2. Administration of ivermectin in the nasopharyngeal tissue attained high concentrations of the drug. In the current study, ivermectin spray was found to be safe and well-tolerated in pigs. Ivermectin is already being used for a decade for scabies and helminthiases. SARS-CoV-2 typically colonizes in the nasopharynx tissue.
Nasal administration would deposit the drug in the upper respiratory pathway exposing the virus to a high concentration of the drug. Over recent years, ivermectins antibacterial and antiviral activities have been observed experimentally. In this study, single or double doses of ivermectin spray (2 mg, 1 puff/nose) or oral tablets 0.2mg/kg were evaluated in pigs. Ivermectin revealed no systemic adverse effects over the entire study period. Following nasal administration, the highest concentration of drug was found in the lung tissue. A second dose of the ivermectin spray increased its concentration significantly.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here